SAN DIEGO, March 4, 2016 /PRNewswire/ -- Epic Sciences, Inc. announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Molecular Medicine Tri-Con 2016, taking place at the Moscone Convention Center, San Francisco March 6-11, 2016.
Dr. Prahalad will give a presentation entitled, "Going Beyond Averages and Enumeration – How Epic Sciences 'No Cell Left Behind' Platform is Driving Novel Insights in Cancer", which will discuss the cellular heterogeneity and unique proteomic and genomic profiles observed in cancer. This session will highlight how Epic Sciences' unique enrichment-free approach enables new insights into cancer that surpass simple enumeration or the genomic averaging that results from the sequencing of tissue biopsy or cfDNA.
The details of the presentation are as follows:
Date: Monday, March 7, 2016
Track: Circulating Tumor Cells
Time: 4:25pm (Pacific Time)
It is increasingly accepted that cancer is a heterogeneous disease comprised of multiple cellular species, each with a unique genomic and proteomic profile. Therefore, cancer is perhaps most treatable when approached as a collection of rare cells that can independently develop resistance to therapies, resulting in metastatic diseases that are often unresponsive to many standard of care treatments.
At Molecular Medicine Tri-Con, Dr. Prahalad will discuss how Epic Sciences' no cell left behind® technology can be used to help triage therapies for improved clinical outcomes. Epic Sciences core technology identifies and characterizes all sub-types of circulating tumor cells (CTCs) in the blood, a technical advantage enabling real-time insights into cancer heterogeneity that are necessary to improve drug development and optimize clinical trials for targeted or combination therapies.
About Epic Sciences
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic Sciences' mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient's journey. The company was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic Sciences' no cell left behind® technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point. Today, we partner with leading pharmaceutical companies and major cancer centers around the world. Epic Sciences' goal is to commercialize our technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
Further information is available on the Company's website, www.epicsciences.com. Stay in touch on LinkedIn Epic Sciences, on Twitter @EpicSciences or on Facebook.com/EpicSciences.
Epic Sciences Contact:
Ryan Ferrell, HDMZ, epic@hdmz.com, +1.312.506.5202
SOURCE Epic Sciences, Inc.